Targeting PCSK9 Reduces Cancer Cell Stemness and Enhances Antitumor Immunity in Head and Neck Cancer

Investigators found that the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) was upregulated in head and neck squamous cell carcinoma (HNSCC) tissues, and higher PCSK9 expression indicated poorer prognosis in HNSCC patients.